A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Aspirin is only modestly effective in the secondary prevention after cerebral ischemia. Studies in other vascular disorders suggest that anticoagulant drugs in patients with cerebral ischemia of presumed arterial (noncardiac) origin might be more effective. The aim of the Stroke Prevention in Reversible Ischemia Trial (SPIRIT) therefore was to compare the efficacy and safety of 30 mg aspirin daily and oral anticoagulation (international normalized ratio [INR] 3.0–4.5). Patients referred to a neurologist in one of 58 collaborating centers because of a transient ischemic attack or minor ischemic stroke (Rankin grade $3) were eligible. Randomization was concealed, treatment assignment was open, and assessment of outcome events was masked. The primary measure of outcome was the composite event “death from all vascular causes, nonfatal stroke, nonfatal myocardial infarction, or nonfatal major bleeding complication.” The trial was stopped at the first interim analysis. A total of 1,316 patients participated; their mean follow‐up was 14 months. There was an excess of the primary outcome event in the anticoagulated group (81 of 651) versus 36 of 665 in the aspirin group (hazard ratio, 2.3; 95% confidence interval [CI], 1.6–3.5). This excess could be attributed to 53 major bleeding complications (27 intracranial; 17 fatal) during anticoagulant therapy versus 6 on aspirin (3 intracranial; 1 fatal). The bleeding incidence increased by a factor of 1.43 (95% CI, 0.96–2.13) for each 0.5 unit increase of the achieved INR. Anticoagulant therapy with an INR range of 3.0 to 4.5 in patients after cerebral ischemia of presumed arterial origin is not safe. The efficacy of a lower intensity anticoagulation regimen remains to be determined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Interobserver agreement for the assessment of handicap in stroke patients
van Swieten, J. C., Koudstaal, P. J., Visser, M. C., Schouten, H. J., & van Gijn, J. (1988) · Stroke · doi:10.1161/01.str.19.5.604 · Cited by 6,512
Self-citationAltman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Antiplatelet Trialists' Collaboration (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 3,126
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,065
EAFT (European Atrial Fibrillation Trial) Study Group (1993) · The Lancet · doi:10.1016/0140-6736(93)92358-z · Cited by 1,741
Palareti, G., Leali, N., Coccheri, S., Poggi, M., Manotti, C., D'Angelo, A., Pengo, V., Erba, N., Moia, M., Ciavarella, N., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)01109-9 · Cited by 1,333
Optimal Oral Anticoagulant Therapy in Patients with Mechanical Heart Valves
Cannegieter, S. C., Rosendaal, F. R., Wintzen, A. R., van der Meer, F. J. M., Vandenbroucke, J. P., & Briet, E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199507063330103 · Cited by 908
Hylek, E. M., Skates, S. J., Sheehan, M. A., & Singer, D. E. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608223350802 · Cited by 789
(1991) · New England Journal of Medicine · doi:10.1056/nejm199110313251801 · Cited by 759
Interobserver agreement for the assessment of handicap in stroke patients.
Bamford, J. M., Sandercock, P. A., Warlow, C. P., & Slattery, J. (1989) · Stroke · doi:10.1161/01.str.20.6.828 · Cited by 693
The Effect of Warfarin on Mortality and Reinfarction after Myocardial Infarction
Smith, P., Arnesen, H., & Holme, I. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007193230302 · Cited by 638
Oates, J. A., Wood, A. J. J., & Hirsh, J. (1991) · New England Journal of Medicine · doi:10.1056/nejm199106273242606 · Cited by 563
The Risk for and Severity of Bleeding Complications in Elderly Patients Treated with Warfarin
Fihn, S. D., Callahan, C. M., Martin, D. C., McDonell, M. B., Henikoff, J. G., White, R. H., & National Consortium of Anticoagulation Clinics* (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-11-199606010-00004 · Cited by 555
(1995) · New England Journal of Medicine · doi:10.1056/nejm199507063330102 · Cited by 425
The clinical spectrum of cerebral amyloid angiopathy: Presentations without lobar hemorrhage
Greenberg, S. M., Vonsattel, J. P. G., Stakes, J. W., Gruber, M., & Finklestein, S. P. (1993) · Neurology · doi:10.1212/wnl.43.10.2073 · Cited by 364
Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia.
Algra, A., & van Gijn, J. (1996) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.60.2.197 · Cited by 256
Sixty Plus Reinfarction Study Research Group (1980) · The Lancet · doi:10.1016/s0140-6736(80)92154-6 · Cited by 254
IMPROVED PRIMARY RENAL ALLOGRAFT SURVIVAL ON CYCLOSPORIN LIMITED TO WOMEN WITH PREVIOUS PREGNANCIES
HUISMAN, R. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91003-9 · Cited by 159
Assessment of a Bleeding Risk Index in Two Cohorts of Patients Treated with Oral Anticoagulants
van der Meer, F. J. M., Rosendaal, F. R., Vandenbroucke, J. P., & Briët, E. (1996) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1650514 · Cited by 154
The E.P.S.I.M. Research Group (1982) · New England Journal of Medicine · doi:10.1056/nejm198209163071201 · Cited by 141
Sloan, M. A., Price, T. R., Petito, C. K., Randall, A. M. Y., Solomon, R. E., Terrin, M. L., Gore, J., Collen, D., Kleiman, N., Feit, F., et al. (1995) · Neurology · doi:10.1212/wnl.45.4.649 · Cited by 122
Questions and Answers on Prothrombin Time Standardisation in Oral Anticoagulant Control
Loeliger, E. A., Poller, L., Samama, M. M., et al. (1985) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1657886 · Cited by 86
Intracerebral hemorrhage after fibrinolytic therapy for acute myocardial infarction.
Wijdicks, E. F. M., & Jack, C. R. (1993) · Stroke · doi:10.1161/01.str.24.4.554 · Cited by 70
Optimal intensity of oral anticoagulant therapy after myocardial infarction
Azar, A. J., Cannegieter, S. C., Deckers, J. W., Briët, E., van Bergen, P. F. M. M., Jonker, J. J. C., & Rosendaal, F. R. (1996) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(96)00020-4 · Cited by 68
(1994) · Circulation · doi:10.1161/01.cir.89.6.2892 · Cited by 68
Chatterjee, A. K., & Tosyali, M. C. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90162-7 · Cited by 4
Cited by
Kernan, W. N., Ovbiagele, B., Black, H. R., Bravata, D. M., Chimowitz, M. I., Ezekowitz, M. D., Fang, M. C., Fisher, M., Furie, K. L., Heck, D. V., et al. (2014) · Stroke · doi:10.1161/str.0000000000000024 · Cited by 5,170
External validity of randomised controlled trials: “To whom do the results of this trial apply?”
Rothwell, P. M. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17670-8 · Cited by 2,544
Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack 2008
(2008) · Cerebrovascular Diseases · doi:10.1159/000131083 · Cited by 2,489
Pharmacology and Management of the Vitamin K Antagonists
Ansell, J., Hirsh, J., Hylek, E., Jacobson, A., Crowther, M., & Palareti, G. (2008) · Chest · doi:10.1378/chest.08-0670 · Cited by 2,118
Sacco, R. L., Adams, R., Albers, G., Alberts, M. J., Benavente, O., Furie, K., Goldstein, L. B., Gorelick, P., Halperin, J., Harbaugh, R., et al. (2006) · Stroke · doi:10.1161/01.str.0000199147.30016.74 · Cited by 1,873
Metadata
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 1997-12
- Volume
- 42
- Issue
- 6
- Pages
- 857-865
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W1522694313
- Cited by
- 480
- References
- 28
- FWCI
- 16.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.